Clinical trial

PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer

NCT05967884

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2023-08-04

PhasePHASE2

Conditions

Breast Cancerverified · MONDO: breast cancer

Interventions

Arm A: Cemiplimab, Arm B: Cemiplimab + DupilumabDRUG

Sponsors & collaborators

Ottawa Hospital Research Institutelead sponsor

Ontario Institute for Cancer Researchcollaborator

Mapped research locations

TorontoOntario, Canada1 OttawaOntario, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05967884 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.